Analgesic Efficacy of Different Liposomal Bupivacaine Doses in the Adductor Canal Block fo
Total knee arthroplasty is a commonly performed orthopaedic surgery for the treatment of end-stage osteoarthritis when conservative management becomes ineffective. TKA is associated with significant acute postoperative pain and many patients experience severe postoperative pain despite the use of multimodal analgesia.
| Condition(s) | Pain, Postoperative, Analgesic Effect, Total Knee Arthroplasty, Liposomal Bupivacaine, Dose Response Relationship, Drug |
|---|---|
| Status | Recruiting |
| Phase | Phase 3 |
| Study type | Interventional |
| Summary | Total knee arthroplasty is a commonly performed orthopaedic surgery for the treatment of end-stage osteoarthritis when conservative management becomes ineffective. TKA is associated with significant acute postoperative pain and many patients experience severe postoperative pain despite the use of multimodal analgesia. Poor acute postoperative pain control impacts rehabilitation, prolongs recovery and increases opioid consumption and chronic post-surgical pain. Liposomal bupivacaine (Exparel, Pacira Pharmaceuticals Inc, Parsippany, New Jersey, USA) is a multivesicular formulation of bupivacaine that prolongs drug release and can extend the duration of analgesia. The adductor canal block (ACB) has been shown to reduce pain intensity and opioid consumption after total knee arthroplasty. The u |
| Who can participate | Inclusion Criteria: * ASA I-III * Age 18-80 years old * Scheduled for elective primary unilateral total knee arthroplasty (TKA) with robotic surgery * Able to speak and understand Cantonese or Mandarin or English * Able to provide informed oral and written consent Exclusion Criteria: * Revision TKA * Single-stage bilateral TKA * Complex primary TKA requiring use of stem/augment/constrained liner * Surgeries with significant intraoperative complications which may alter rehabilitation protocol eg collateral ligament injury, fracture requiring fixation * Known allergy to opioids, local anaesthetic drugs, paracetamol, non-steroidal anti-inflammatory drugs (NSAIDS) including COX-2 inhibitors * History of chronic pain other than chronic knee pain * History of immunosuppression * Chronic use of g |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Lead sponsor | The University of Hong Kong |
| Locations | Hong Kong, Hong Kong, Hong Kong |
| Start date | 2025-09-04 |
| NCT ID | NCT06740214 |
| Official listing | https://clinicaltrials.gov/study/NCT06740214 |